Skip to main content

Table 2 Treatment characteristics

From: Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year

Treatment

Number (percentage) of patients

csDMARDs/biologics started at baseline, n (%)

152 (91.0)

 - MTX, n (%)

147 (88.0)

 - Other csDMARDs, n (%)

4 (2.4)

 - csDMARD triple therapy, n (%)

1 (0.6)

Anti-TNF at baseline, n (%)

1 (0.6)

Anti-TNF ever, n (%)

18 (10.8)

Other bDMARDs

6 (3.6)

Oral glucocorticoids, n (%)

138 (82.6)

Calcium supplements, n (%)a

79 (49.1)

Bisphosphonates, n (%)b

7 (6.0)

  1. Abbreviations: MTX methotrexte, cDMARDs conventional disease modifying anti-rheumatic drugs, TNF tumor necrosis factor, bDMARDs biologic disease modifying anti-rheumatic drugs
  2. aData available for 161 patients
  3. bData available for 124 patients